PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2016-05-09
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-06-30 was $37.80K, a 30.51% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $68.40K, a 94.78% decline from fiscal 2014.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $1.31M.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2012 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2011 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | $0.00 derived: sum of 2 quarters · filed 2016-05-09 | $0.00 derived: sum of 3 quarters · filed 2016-05-09 | $37.80K derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $0.00 derived: sum of 2 quarters · filed 2016-03-14 | $37.80K derived: sum of 3 quarters · filed 2016-03-14 | $68.40K 10-K · filed 2016-03-14 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $37.80K derived: sum of 2 quarters · filed 2015-11-09 | $68.40K 10-Q · filed 2015-11-09 | $69.25K derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-06-30 | $37.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $68.40K 10-Q · filed 2015-08-10 | $69.25K derived: sum of 3 quarters · filed 2015-08-10 | $77.94K derived: sum of 4 quarters · filed 2015-08-10 |
| 2015-03-31 | $30.60K 10-Q · filed 2015-05-08 | $31.45K derived: sum of 2 quarters · filed 2015-05-08 | $40.14K derived: sum of 3 quarters · filed 2015-05-08 | $94.54K derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | $847.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $9.54K derived: sum of 2 quarters · filed 2015-03-16 | $63.94K derived: sum of 3 quarters · filed 2015-03-16 | $1.31M 10-K · filed 2015-03-16 |
| 2014-09-30 | $8.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $63.09K derived: sum of 2 quarters · filed 2014-11-07 | $1.31M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $54.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.30M 10-Q · filed 2014-08-08 | ||
| 2014-03-31 | $1.25M 10-Q · filed 2014-05-12 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 | $0.00 derived: sum of 2 quarters · filed 2013-05-10 | $0.00 derived: sum of 3 quarters · filed 2013-05-10 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |